Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Petros Pharmaceuticals Inc
(NQ:
PTPI
)
0.6400
+0.0001 (+0.02%)
Streaming Delayed Price
Updated: 9:31 AM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,467
Open
0.6400
Bid (Size)
0.6350 (2)
Ask (Size)
0.6600 (6)
Prev. Close
0.6399
Today's Range
0.6400 - 0.6400
52wk Range
0.6020 - 5.240
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
April 23, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
April 16, 2024
Via
ACCESSWIRE
Performance
YTD
-54.93%
-54.93%
1 Month
-58.71%
-58.71%
3 Month
-43.86%
-43.86%
6 Month
-59.24%
-59.24%
1 Year
-85.87%
-85.87%
More News
Read More
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 02, 2024
Via
Benzinga
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
February 14, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
January 24, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider
December 12, 2023
Via
ACCESSWIRE
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
April 02, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 02, 2024
Via
Benzinga
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
April 02, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
March 19, 2024
Via
ACCESSWIRE
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
March 11, 2024
Via
TheNewswire.com
Exposures
Product Safety
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
December 05, 2023
Via
ACCESSWIRE
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA
October 19, 2023
Via
ACCESSWIRE
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
March 11, 2024
Via
News Direct
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 30, 2024
Via
Benzinga
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 30, 2024
Via
Benzinga
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
January 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 17, 2024
Via
Benzinga
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
January 17, 2024
Via
ACCESSWIRE
Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
December 13, 2023
Via
Benzinga
Exposures
Product Safety
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
December 12, 2023
Via
ACCESSWIRE
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
October 30, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 13, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.